<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838694</url>
  </required_header>
  <id_info>
    <org_study_id>IVXCpn001</org_study_id>
    <nct_id>NCT01838694</nct_id>
  </id_info>
  <brief_title>Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invion, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety, tolerability, and efficacy of 4
      weeks intravenous treatment with Cpn10 in subjects with mild to moderate active SLE.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Serum Interleukin 6 (IL-6) Levels at the End of Active Dosing, Comparing Treatment to Placebo Cohort.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ala-Cpn10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ala-Cpn10</intervention_name>
    <arm_group_label>Ala-Cpn10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (ALL must be met):

        To be entered on study, subjects must meet the following criteria:

          1. Male or female

          2. Age 18 - 75 years

          3. Patients fulfilling at least 4 criteria for SLE as defined by the American College of
             Rheumatology (ACR)

          4. Laboratory values as follows:

             Documented ANA titer ≥ 1:160 or positive anti-dsDNA antibodies at, or any time prior
             to screening (verifiable laboratory result)

          5. Not pregnant or breast-feeding

          6. If corticosteroids are required for disease stability prior to study entry, able to
             tolerate a stable dose of ≤ 0.3 mg/kg/day of prednisone or equivalent for the duration
             of the study.

          7. Agreement to use an effective form of contraception for the duration of the study.

          8. Ability to understand and give consent.

          9. Willing to participate and able to comply with the study requirements, procedures and
             visits.

             Mild SLE only

         10. Present with mild active SLE disease

             Moderate SLE only

         11. Present with active SLE disease based on SLE disease activity score (SLEDAI) ≥4 and
             ≤10

         12. MCP-1 urinary level &gt; 35 pg/ml

         13. IL-6 serum level &gt; 10 pg/ml

         14. Meets the American College of Rheumatology (ACR) conditions for &quot;renal disorder&quot; as
             one of the diagnostic criteria for SLE i.e.

               1. Persistent proteinuria between 0.5 and 1.0 grams per day or &gt; than 3+ by dipstick
                  OR

               2. Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed

             OR

         15. Physician (Pathologist) diagnosis of lupus nephritis of no greater severity than:

               1. Class I - Minimal mesangial lupus nephritis, OR

               2. Class II - Mesangial proliferative lupus nephritis, in accordance with the
                  International Society of Nephrology (ISN) and the Renal Pathology Society (RPS)
                  2003 histological classification.

             With diagnosis made ≥ 6 months prior to study commencement.

         16. If inclusion criteria #15 is met, subject must be receiving stable Standard of Care,
             including hydroxychloroquine, treatment appropriate for class I-II nephritis.

        Exclusion Criteria (NONE can apply):

          1. Active severe SLE flare with central nervous system (CNS) and/or renal manifestations,
             pericarditis, active pleuritis, active peritonitis or other SLE manifestations
             requiring treatment not allowed by the study protocol within 4 weeks of screening

          2. Pregnant or breast-feeding

          3. Lack of peripheral venous access.

          4. History of cardiovascular disease. An acute cardiovascular event within 12 months of
             study entry, including arterial or venous thrombosis (blood clots).

          5. Requirement for a stable dose of corticosteroid &gt;0.3 mg/kg/day of prednisone or
             equivalent.

          6. Active therapy with human or murine monoclonal antibodies (i.e. belimumab), within 2
             months of study entry.

          7. Any experimental therapy within 3 months of study entry.

          8. Therapy with cyclophosphamide p.o or parenteral; pulse methylprednisolone or IVIG
             within 4-6 weeks.

          9. Subjects being treated with sulfonylureas.

         10. Subjects with any the following laboratory abnormalities: serum creatinine &gt;3.0 mg/dL,
             WBC &lt;3,500/μL, ANC &lt;3,000/μL, absolute lymphocyte count ≤500/μL, Hgb &lt;8.0 g/dL,
             platelets &lt;50,000/μL, ALT and/or AST &gt;1.5 x upper limit of normal (ULN), alkaline
             phosphatase &gt;1.5 ULN.

         11. Personal or psychiatric condition that precludes the subject being able to comply with
             the study requirements or understand and agree to the informed consent process.

         12. Recent systemic bacterial, fungal, viral, or parasitic infections. Have required
             management/treatment or hospitalization for any infection within the last 4 weeks
             before screening.

         13. History of malignancy - except completely excised basal cell carcinoma.

         14. Impaired hepatic function

         15. Body weight of 260lbs/120kg or more (BMI &gt; 35)

         16. History of tuberculosis (TB) or active, continuing treatment for TB

         17. History of or current alcohol or substance abuse

             Mild SLE only

         18. Active lupus nephritis and/or severe renal impairment (estimated or measured GFR &lt; 50%
             predicted for age and gender)

             Moderate SLE only

         19. Subjects with recently diagnosed lupus nephritis (diagnosis made &lt;6 months prior to
             commencement of study

         20. Subjects with active urinary sediment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abel Buchheim Pharmaceutical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Arthritis and Osteoporosis Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2013</study_first_posted>
  <results_first_submitted>September 1, 2016</results_first_submitted>
  <results_first_submitted_qc>December 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2017</results_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Early pregnancy factor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Ala-Cpn10</title>
          <description>Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range of 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Ala-Cpn10</title>
          <description>Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range of 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="18"/>
                    <measurement group_id="B2" value="43" spread="15"/>
                    <measurement group_id="B3" value="45" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Serum Interleukin 6 (IL-6) Levels at the End of Active Dosing, Comparing Treatment to Placebo Cohort.</title>
        <time_frame>4 weeks</time_frame>
        <population>Analysis Population reflects participants for whom adequate analyzable samples were collected</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Ala-Cpn10 - 10mgs in Mild SLE</title>
            <description>Recombinant minimally modified Chaperonin10 (Cpn10) 10mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
          </group>
          <group group_id="O3">
            <title>Ala-Cpn10 - 30mgs in Mild SLE</title>
            <description>Recombinant minimally modified Chaperonin10 (Cpn10) 30mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
          </group>
          <group group_id="O4">
            <title>Ala-Cpn10 - 100mgs in Mild SLE</title>
            <description>Recombinant minimally modified Chaperonin10 (Cpn10) 100mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
          </group>
          <group group_id="O5">
            <title>Ala-Cpn10 - 30mgs in Moderate SLE</title>
            <description>Recombinant minimally modified Chaperonin10 (Cpn10) 30mg twice weekly administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Serum Interleukin 6 (IL-6) Levels at the End of Active Dosing, Comparing Treatment to Placebo Cohort.</title>
          <population>Analysis Population reflects participants for whom adequate analyzable samples were collected</population>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="24.7"/>
                    <measurement group_id="O2" value="987.7" spread="2202.1"/>
                    <measurement group_id="O3" value="-82.5" spread="20.4"/>
                    <measurement group_id="O4" value="-29.7" spread="59.1"/>
                    <measurement group_id="O5" value="5000" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 days following each patient's discontinuation of the study, for up to 9 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Ala-Cpn10</title>
          <description>Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range (0.16mg/kg [10mg twice weekly] to 5mg/kg [300mg twice weekly]) administered intravenously by infusion over 60 minutes.
Ala-Cpn10</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mitchell Glass, M.D., EVP of R&amp;D</name_or_title>
      <organization>Invion, Inc.</organization>
      <phone>+61 7 3295 0500</phone>
      <email>mitchell.glass@inviongroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

